One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Denmark said on Monday it would spend 14.6 billion Danish kroner ($2.05 billion) boosting its military capabilities in the ...

Denmark said on Monday it would spend 14.6 billion Danish crowns ($2.05 billion) boosting its military presence in the Arctic ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

President Trump reportedly held a “fiery” call with Denmark’s Prime Minister Mette Frederiksen over the president’s insistence that U.S. control of Greenland is necessary for American ...

Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...

Donald Trump insisted he was serious in his determination to take over Greenland in a fiery telephone call with Denmark’s prime minister, according to senior European officials. The US president ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

As Alzheimer’s disease is the most common form of dementia — affecting an estimated 6.7 million Americans — it’s not surprising that people who experience memory loss may suspect AD.